Highest-materiality recent filing
MediciNova terminates $30M standby equity purchase agreement with Yorkville
Terminated SEPA with YA II PN, LTD. effective Sept 8, 2026; no fees or outstanding obligations.
MediciNova enters new employment agreements with CEO and CMO
CEO Dr. Yuichi Iwaki: base salary $690,246, bonus target 55% of base.
MediciNova shareholders reject proposal to increase authorized shares to 247M at 2026 annual meeting
Class I directors Hikedi Nagao and Nicole Lemerond elected with ~20.9M and ~21.5M votes for, respectively.
MediciNova FY2025 net loss per share $0.24, operating loss $13.3M, cash down to $30.8M
Net loss attributable to shareholders $12.0M ($0.24 per share) vs $11.0M ($0.23) in FY2024.
MediciNova enters equity distribution agreement for up to $50M at-the-market offering
Agreement with Lucid Capital Markets as sales agent for at-the-market sales of common stock.
MediciNova enters $30M equity purchase agreement with Yorkville at 97% of VWAP
May sell up to $30M in common stock over 36 months via periodic advances.
Carolyn Beaver elected as Class III director with 22,024,122 votes for, 8,936,487 against, 923,050 abstain.
MediciNova updates investor presentation for March 2025 meetings
Company furnished updated slide presentation for use at investor meetings on March 11, 2025.
MediciNova stockholders re-elect two directors, ratify auditor at annual meeting
Yuichi Iwaki and Kazuko Matsuda re-elected as Class II directors; votes: 24.3M for, 7.9M against each.
MediciNova VP Geoffrey O'Brien resigns as employee, to stay as consultant
Geoffrey O'Brien, VP, retires from full-time employment effective April 2, 2024.
MediciNova appoints Nicole Lemerond to Board, filling vacancy
Lemerond appointed as Class I director, term expiring at 2026 Annual Meeting.
MediciNova receives two Nasdaq deficiency notices for board and audit committee independence
Received Audit Committee Notice on June 15, 2023 due to committee having two independent members instead of three.
Stockholders elect director, ratify auditor, approve 2023 equity plan
Hideki Nagao elected Class I director with 19.7M for, 7.5M against, 1.4M abstain, 2.7M broker non-vote.
MediciNova director Jeff Himawan to not stand for re-election due to health reasons
Dr. Jeff Himawan notified Board he will not stand for re-election as Class I director at 2023 annual meeting.
MediciNova CFO Douglas Paulin resigns; Jason J. Kruger appointed as new CFO
Effective June 16, 2022, Douglas Paulin resigned as CFO; Jason J. Kruger appointed as CFO and Principal Financial Officer.
MediciNova stockholders elect director, ratify auditor, approve say-on-pay
Carolyn Beaver elected Class III director with 22.2M for, 4.6M against, 0.8M abstain (3.2M broker non-vote).
MediciNova may receive portion of Genzyme's damages from Novartis Zolgensma patent suit
Genzyme filed First Amended Complaint on Feb 23, 2022 in Delaware court adding U.S. Patent No. 9,051,542 against Novartis over Zolgensma.
Edward Stepanow resigned as CFO effective July 31, 2021; no reason given.
MediciNova signs 5-year lease for La Jolla HQ; base rent $14,464/month
Lease term of 60 months from Feb 1, 2022 to Jan 31, 2027, for 4,383 sq ft at 4275 Executive Square, La Jolla.
On March 26, 2024, Geoffrey O’Brien informed MediciNova, Inc. (the “Company”) of his decision to retire from full-time employment and resign from his employment with the Company, effective as of April 2, 2024.
On August 4, 2023, the Board of Directors (the “Board”) of MediciNova, Inc. (the “Company”) appointed Nicole Lemerond as a member of the Board, effective immediately, filling an existing vacancy on the Board.
On April 20, 2023, Jeff Himawan, Ph.D., a member of the Board of Directors (the “Board”) of MediciNova, Inc. (the “Company”) notified the Board that he will not stand for re-election as a Class I director of the Company at the Company’s 2023 annual meeting of stockholders (the “Annual Meeting”) due solely to a personal decision related to health reasons.
Effective June 16, 2022, Douglas Paulin resigned as Chief Financial Officer of MediciNova, Inc.
In addition, effective August 1, 2021, the Board appointed Douglas Paulin, CPA, of the accounting services firm Signature Analytics San Diego LLC (“Signature Analytics”) to serve as Chief Financial Officer and Principal Financial Officer of the Company.
Effective July 31, 2021, Edward Stepanow resigned as Chief Financial Officer of MediciNova, Inc. (the “Company”).
Max materiality 0.65 · Median 0.35 · Most common event other_material